Aitua's MicroEye gets European CE approval

Cambridge, UK-based Aitua, the life science intellectual property commercialization company, says that one of its portfolio companies, Probe Scientific, medical device company, has been awarded regulatory approval to market its MicroEye device in Europe. The sterile single-use, minimally invasive blood sampling device allows continuous blood sampling in collaboration with pre-existing access devices, thereby avoiding repeated needle puncture for the patient, noted Aitua.

CE marking, an important milestone for Probe, allows the device to begin clinical evaluations with selected customers in the UK and Europe. Leading clinical researchers are keen to evaluate the MicroEye and to demonstrate its value in solving blood collection problems associated with cutting edge medical research and clinical trials. MicroEye is the first product of the series; future products will employ Probe's proprietary platform tool to focus on automated sampling and sensing technologies for immediate analysis at a patient's bedside in a wide range of clinical markets.